A5070919431- Galectins and Cancer Biology
- Glycosylation and Glycoproteins Research
- Toxin Mechanisms and Immunotoxins
- Peptidase Inhibition and Analysis
- Protein Tyrosine Phosphatases
- Melanoma and MAPK Pathways
- Cancer Mechanisms and Therapy
- Protein Kinase Regulation and GTPase Signaling
- Signaling Pathways in Disease
National Institute of Pharmaceutical Education and Research
2020-2021
National Institute of Pharmaceutical Education and Research
2020
The Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) has been rapidly transmitting and leaving its footprints across the globe. Stringent measures like complete lockdown extensive testing have employed by many countries to slow it down in tracks until a viable treatment is found. Therefore, current scenario, prompt solutions need be uncovered tackle virus. In present study, 330 galectin inhibitors were tested against SARS-CoV-2 spike (S) protein with aid of molecular docking...
Allosteric inhibitors of mitogen-activated protein kinase 1 (MEK1) reveal distinct interactions with MEK1 activation loop residues. The structural analyses will determine whether, and how, suppress the phosphorylation may guide future therapeutic development. In this study, we explored suppression mechanism process in presence MEK allosteric inhibitors, such as selumetinib, trametinib, cobimetinib, CH5126766, by employing molecular dynamics simulations accompanied principal component...
Galectin-3 is a carbohydrate-binding protein that plays crucial role in cancer and fibrosis. Its inhibitors have largely evolved from naturally occurring saccharides to many synthetic forms with significantly improved affinity. However, there haven't been any substantial sizeable structure-activity relationship studies order develop potent selective inhibitors. This study presents an extensively curated first of its kind dualfield-based 3D-QSAR model which sheds light on development novel...